Biohacker Bryan Johnson Diagnosed with Autoimmune Gastritis, Plans Experimental Treatment Approach

Bryan Johnson, the 48-year-old tech entrepreneur and prominent anti-aging influencer, has publicly disclosed that he is battling autoimmune gastritis (搜索)搜索该疾病 (AIG), a hidden condition in which the immune system attacks the stomach lining. In a post on X, Johnson wrote: "I have an autoimmune disease. My stomach is eating itself." He explained that the illness often goes undetected, affecting an estimated 2–5% of people, and can lead to nutritional deficiencies, anemia, and elevated cancer risk over time.

The diagnosis marks a significant turn in Johnson's highly publicized longevity journey, which includes his $1 million-per-year "Immortals Care" protocol aimed at reversing biological aging.

A Diagnostic Odyssey Spanning Over a Decade

Johnson's path to diagnosis began long before his current health optimization efforts. He recounted how his health journey started with hypothyroidism (搜索)搜索该疾病, diagnosed at age 21, which he managed with hormone replacement therapy including levothyroxine查看药品详情 and Armour Thyroid查看药品详情. For over a decade, however, he struggled with low ferritin levels despite normal hemoglobin and hematocrit — a sign of iron deficiency that was repeatedly dismissed by doctors.

"On the surface, my low ferritin was easy to dismiss by most standards of care. My hemoglobin and hematocrit were normal," Johnson explained. "Ferritin measures stored iron, while hemoglobin measures circulating iron, and because the body drains its reserves first to keep hemoglobin normal, you can be fully iron deficient with a perfectly normal hemoglobin and hematocrit."

After overhauling his medical team earlier this year, a systematic investigation was launched. A colonoscopy came back clean — described by his gastroenterologist as "better than 95% of colonoscopies of men" — ruling out hidden bleeding from colon cancer or polyps. However, his team had anticipated this outcome and ordered a bi-directional endoscopy, examining the entire intestinal tract.

Fifteen minutes before the procedure, blood results returned showing elevated anti-parietal cell antibodies (搜索)搜索该靶点 (APCA) at roughly five times the upper limit of normal — 103 Units/mL against a ceiling of 20 Units/mL. Biopsies taken from three regions of Johnson's stomach confirmed the diagnosis, showing "clear signs of early autoimmune gastritis (搜索)搜索该疾病: early atrophy confined to the acid-producing lining, with the rest of the stomach still spared."

Thyrogastric Syndrome: Three Interlinked Conditions

Johnson's case exemplifies what is known as thyrogastric syndrome — the well-documented connection between thyroid and stomach autoimmunity. He described his situation as "never one problem. It was three, linked to one another: the iron deficiency, the autoimmune gastritis (搜索)搜索该疾病 driving it, and the autoimmune thyroid disease alongside it."

The interplay is bidirectional: low iron impairs the conversion of thyroid hormone into its active form, while an underactive thyroid impairs how the body uses iron. "Each made the other harder to fix," Johnson noted.

The diagnostic challenge Johnson faced is not uncommon. He cited research indicating that in one study of people with precancerous gastric lesions, roughly 18% carried the autoimmune antibodies, yet only about 1% had ever been diagnosed. "And the earliest clue, low ferritin, is the one standard medicine waves through. Low iron stores get normalized and rarely investigated at all when anemia hasn't shown up yet. That blind spot is what hid mine for a decade."

Immediate Treatment and Long-Term Strategy

Johnson's iron deficiency has now been corrected with a 1,000 mg Monoferric查看药品详情 iron infusion, chosen for its ability to deliver a full dose in a single infusion and its lower likelihood of causing hypophosphatemia compared to other intravenous iron formulations.

However, Johnson acknowledged the current limitations of standard care: "When AIG is discovered today, standard medical care concedes defeat, stating that nothing can be done except managing the condition, no matter how awful or lethal the effects."

Refusing to accept this paradigm, Johnson outlined a four-tier experimental approach:

• Tier 1 (current): Protective and supportive measures including zinc-L-carnosine and acid replacement with betaine HCl and pepsin under physician supervision.
• Tier 2: Targeting signaling pathways — JAK/STAT, GSK-3, IL-17 — and dampening the gastrin drive with netazepide.
• Tier 3: Cellular reset approaches using induced regulatory T cells (iTregs).
• Tier 4 (frontier): Engineered T-cell therapy such as CAR-T or CAAR-T, custom AI-designed antibodies, or synthetic proteins capable of specifically inactivating or destroying the rogue immune cells attacking the stomach lining.

Routine monitoring will track ferritin and iron, B12, the pepsinogen I/II ratio, gastrin (搜索)搜索该靶点, and chromogranin A. "Gastrin is the dial to watch," Johnson wrote. "If it climbs, the disease is advancing, and the risk of gastric neuroendocrine tumors climbs with it."

Johnson was transparent about the experimental nature of his plan: "To be clear: there's no approved cure for autoimmune gastritis (搜索)搜索该疾病 today. Medicine treats it as something to manage, not solve. Tiers 2 through 4 are investigational preclinical evidence at best, and in several cases therapies that still have to be built."

He extended an open invitation to researchers working on autoimmune gastritis (搜索)搜索该疾病, antigen-specific tolerance, regulatory T cells, or CAAR-T for organ-specific autoimmunity, signaling his intent to push beyond conventional management toward a potential cure. "In the age of AI, multiomics, and custom-built DNA, proteins, and cells, no condition should be presumed incurable simply because no one has yet tried to cure it with today's stack."